NAIL FUNGUS DRUG EFFICACY BASED ON CLINICAL ENDPOINTS
This article was originally published in The Tan Sheet
Executive Summary
NAIL FUNGUS DRUG EFFICACY BASED ON CLINICAL ENDPOINTS, not a negative mycological culture, is accept- able, FDA's Dermatologic Drags Advisory Committee concurred at a Sept. 23 meeting. "I think we've got consensus here," said committee Chair Wilma Bergfeld, MD, Cleveland Clinic Foundation. "The basis of success is a cleared nail bed."